ANI Pharmaceuticals (ANIP) SVP sells 2,772 common shares

Q: At what price were Ori Gutwerg’s ANI Pharmaceuticals (ANIP) shares sold?

The shares were sold at $79.50 per share. The Form 4 lists a transaction price per share of $79.5000 for the 2,772 shares of ANI Pharmaceuticals Common Stock disposed of in this open-market sale.

Q: How many ANI Pharmaceuticals (ANIP) shares does Ori Gutwerg own after this sale?

After the sale, Ori Gutwerg directly owns 78,696 shares. The Form 4 discloses total shares following the transaction of 78,696 Common Stock shares held with direct ownership reported for the SVP, Generics.

Q: Was the ANI Pharmaceuticals (ANIP) transaction by Ori Gutwerg a buy or a sell?

The transaction was a sell. The Form 4 categorizes it with transaction code “S” and describes it as an open-market sale, with transaction_direction explicitly labeled as “sell” and transaction_action as “open-market sale.”

Filing Impact

(Moderate)

Filing Sentiment

(Negative)

Form Type

Rhea-AI Filing Summary

ANI Pharmaceuticals senior vice president of generics Ori Gutwerg reported an open-market sale of Common Stock. On May 12, 2026, he sold 2,772 shares at a price of $79.50 per share. After this transaction, he directly owns 78,696 shares of ANI Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 2,772 shares ($220,374)

Net Sell 1 txn

Insider Gutwerg Ori

Role SVP, GENERICS

Sold 2,772 shs ($220K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,772	$79.50	$220K

Holdings After Transaction: Common Stock — 78,696 shares (Direct, null)

Footnotes (1)

Key Figures

Shares sold: 2,772 shares Sale price per share: $79.50 per share Shares owned after sale: 78,696 shares +2 more

5 metrics

Shares sold 2,772 shares Common Stock open-market sale on May 12, 2026

Sale price per share $79.50 per share Price for the 2,772 Common Stock shares sold

Shares owned after sale 78,696 shares Total Common Stock directly owned following the transaction

Sell transactions count 1 transaction Single non-derivative sale reported in transactionSummary

Net buy/sell shares -2,772 shares Net-sell direction for this Form 4

Key Terms

Common Stock, open-market sale, transaction_price_per_share, total_shares_following_transaction

4 terms

Common Stock financial

"security_title: "Common Stock" for the reported transaction"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

open-market sale financial

"transaction_action: "open-market sale" describes the disposition"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

total_shares_following_transaction financial

"total_shares_following_transaction: "78696.0000" shows post-sale holdings"

Form 4 Insider Transactions: What Each Field Means →

05/13/2026 - 04:15 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Gutwerg Ori

(Last)

(First)

(Middle)

C/O ANI PHARMACEUTICALS, INC.

104 CARNEGIE CENTER, SUITE 300

(Street)

PRINCETON

NEW JERSEY

08540

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ANI PHARMACEUTICALS INC [ ANIP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, GENERICS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/12/2026		S		2,772	D	$79.5	78,696	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

Remarks:

	/s/ Ori Gutwerg, by attorney-in-fact Meredith W. Cook	05/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did ANI Pharmaceuticals (ANIP) report for Ori Gutwerg?

ANI Pharmaceuticals reported that Ori Gutwerg sold shares of Common Stock. On May 12, 2026, the SVP, Generics completed an open-market sale of the company’s common shares and updated his direct ownership position in the filing.

How many ANI Pharmaceuticals (ANIP) shares did Ori Gutwerg sell?

Ori Gutwerg sold 2,772 shares of ANI Pharmaceuticals Common Stock. The Form 4 shows a single non-derivative transaction labeled as an open-market sale, reducing his directly held share count by that exact number of shares.

At what price were Ori Gutwerg’s ANI Pharmaceuticals (ANIP) shares sold?

The shares were sold at $79.50 per share. The Form 4 lists a transaction price per share of $79.5000 for the 2,772 shares of ANI Pharmaceuticals Common Stock disposed of in this open-market sale.

How many ANI Pharmaceuticals (ANIP) shares does Ori Gutwerg own after this sale?

After the sale, Ori Gutwerg directly owns 78,696 shares. The Form 4 discloses total shares following the transaction of 78,696 Common Stock shares held with direct ownership reported for the SVP, Generics.

Was the ANI Pharmaceuticals (ANIP) transaction by Ori Gutwerg a buy or a sell?

The transaction was a sell. The Form 4 categorizes it with transaction code “S” and describes it as an open-market sale, with transaction_direction explicitly labeled as “sell” and transaction_action as “open-market sale.”

Does the ANI Pharmaceuticals (ANIP) Form 4 show any option exercises or derivative trades?

No derivative transactions are listed in this Form 4 excerpt. The filing’s derivativeSummary is empty and derivativeTransactionCount is zero, indicating only a single non-derivative Common Stock sale was reported for this date.